1,853 material Form 8-K filings that 1,500 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
AMC Global Media agreed on September 4, 2026 to settle breach-of-contract claims brought by Walking Dead creators and rights holders, with total consideration of $120 million. The company now expects 2026 free cash flow of about $150 million, down from the about $220 million it indicated on July 30, 2026, while its revenue and adjusted operating income outlook is unchanged.
Total settlement consideration is $120 million: $85 million cash due by September 18, 2026, and $35 million due by January 31, 2027.
The company expects a charge of about $85 million in the quarter ending September 30, 2026.
2026 free cash flow outlook falls to about $150 million from about $220 million; excluding the one-time items, guidance is unchanged.
The trial had been scheduled to begin October 27, 2026; the case is being dismissed with prejudice.
Matinas BioPharma received an NYSE American notice on August 31, 2026, saying it fails the $2.0 million stockholders' equity standard because its equity was $1.8 million as of June 30, 2026. The company already had two other listing deficiencies, and the exchange has granted a plan period through October 2, 2027, after which delisting proceedings may start if it has not regained compliance.
Stockholders' equity was $1.8 million as of June 30, 2026, below the $2.0 million minimum under NYSE American Section 1003(a)(i).
The company is also out of compliance with Sections 1003(a)(ii) ($4.0 million) and 1003(a)(iii) ($6.0 million), as disclosed in earlier filings.
The NYSE American accepted the company's May 4, 2026 plan and set a plan period deadline of October 2, 2027.
Shares continue to trade as MTNB on the NYSE American during the plan period, with a .BC indicator attached.
Pantages Capital Acquisition Corporation received a Nasdaq notice on September 2, 2026, saying it did not meet the 400 Total Holders requirement for continued listing on the Nasdaq Global Market. Nasdaq says the notice is a deficiency notification, not an imminent delisting, and has no immediate effect on trading, but the company must submit a compliance plan by October 19, 2026.
Nasdaq Listing Rule 5450(a)(2) requires at least 400 Total Holders; the company was found not in compliance.
Notice received September 2, 2026 from the Nasdaq Listing Qualifications Department.
Compliance plan due no later than October 19, 2026; if accepted, Nasdaq may grant up to 180 calendar days to comply.
The company intends to submit a plan on or before October 19, 2026.
Curanex Pharmaceuticals said Nasdaq has closed its bid price deficiency matter after the company's stock closed at or above $1.00 for 10 consecutive business days following a 1-for-20 reverse stock split effected August 20, 2026. The company remains listed on The Nasdaq Capital Market, which removes the immediate risk of delisting tied to the low share price.
Nasdaq notified the company on November 5, 2025 that its bid price had been below $1.00 for 30 consecutive business days.
The company effected a 1-for-20 reverse stock split on August 20, 2026.
On September 3, 2026, Nasdaq confirmed compliance based on closing bid prices from August 20 to September 2, 2026, and closed the matter.
Arcadia Biosciences received a Nasdaq letter dated August 31, 2026, saying its stockholders' equity of $633,000 at June 30, 2026, was below the $2.5 million minimum for continued listing on the Nasdaq Capital Market. The company's common stock will continue to trade on the Nasdaq Capital Market for now, but the company must submit a compliance plan, and there is no assurance Nasdaq will accept it.
Reported stockholders' equity was $633,000 as of June 30, 2026, versus the $2.5 million minimum under Nasdaq Listing Rule 5550(b)(1).
The company does not meet Nasdaq's alternative market value or net income standards either.
The compliance plan is due to Nasdaq by October 15, 2026; if accepted, Nasdaq may grant up to 180 calendar days to show compliance.
If Nasdaq rejects the plan, the company may appeal to a Nasdaq Hearings Panel, which ordinarily stays any suspension or delisting action.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.